Access on ReachMD

play
loading
Your Comprehensive Hub For Excellence In CKM Health Education

CLOSE
loading

Your Comprehensive Hub for Excellence in Heart Failure, Chronic Kidney Disease and Diabetes

Through expert interviews, case discussions, expert panels, and patient perspectives, renowned global experts share the latest evidence-based guidance and real-world insights for practicing clinicians. This learning center features education spanning heart failure, chronic kidney disease with type 2 diabetes, chronic kidney disease with type 1 diabetes, and non-diabetic chronic kidney disease.

Join our growing community of cardiology, nephrology, endocrinology, and primary care clinicians by engaging with this educational content and sharing it with your colleagues and care teams.

Together, we can advance the future of Cardio-Kidney-Metabolic care worldwide!

~50% of patients with chronic kidney disease (CKD) stages 4 to 5 also have CVD

 ~ 50 % 

of patients with chronic kidney disease (CKD) stages 4 to 5 also have CVD1

~40% of individuals with diabetes develop diabetic kidney disease

 ~ 40 % 

of individuals with diabetes develop diabetic kidney disease2

~25% prevalence of concurrent comorbidities associated with CKM worldwide

 ~ 25 % 

prevalence of concurrent comorbidities associated with CKM worldwide3

Educational Programs

No Patient with CKD Left Behind! Emerging CKD Therapies in T1D

CME/CE

No Patient with CKD Left Behind! Emerging CKD Therapies in T1D
Engaging Your Patient: Shared Decision-Making in HF With LVEF ≥40%

CME/CE

Engaging Your Patient: Shared Decision-Making in HF With LVEF ≥40%
The Fifth Pillar? Closing the Gap in HFrEF

CME/CE

The Fifth Pillar? Closing the Gap in HFrEF
Case-Based Approach: Optimizing Cardio-Kidney-Metabolic Outcomes in Individuals With T2D & CKD

CME/CE

Case-Based Approach: Optimizing Cardio-Kidney-Metabolic Outcomes in Individuals With T2D & CKD
The Hidden Threat: Transforming CKD Care Across the Diabetes Spectrum

CME/CE

The Hidden Threat: Transforming CKD Care Across the Diabetes Spectrum
Finerenone vs Placebo in Type 1 Diabetes and CKD: Updates From the Phase 3 FINE-ONE Trial From the Kidney Meeting 2025 in Houston

CME/CE

Finerenone vs Placebo in Type 1 Diabetes and CKD: Updates From the Phase 3 FINE-ONE Trial From the Kidney Meeting 2025 in Houston
Implications of the FINE-ONE Trial: How Might Recently Presented Data From the 2025 Kidney Meeting Influence the Current Treatment Paradigm for Type 1 Diabetes and CKD?

CME/CE

Implications of the FINE-ONE Trial: How Might Recently Presented Data From the 2025 Kidney Meeting Influence the Current Treatment Paradigm for Type 1 Diabetes and CKD?
New Data From the CONFIDENCE Trial: The Effect of Combination Empagliflozin and Finerenone on UACR and eGFR in CKD and Type 2 Diabetes

CME/CE

New Data From the CONFIDENCE Trial: The Effect of Combination Empagliflozin and Finerenone on UACR and eGFR in CKD and Type 2 Diabetes
The Impact of Finerenone Plus Empagliflozin on Hyperkalemia in the CONFIDENCE Trial

CME/CE

The Impact of Finerenone Plus Empagliflozin on Hyperkalemia in the CONFIDENCE Trial
Optimizing Patient Outcomes in CKD & T2D Care With CONFIDENCE

CME/CE

VICTOR Trial Results: Vericiguat Efficacy and Safety Across Baseline Background Therapy in Contemporary Ambulatory Patients With HFrEF
VICTOR Prespecified Analysis Results: Vericiguat Effects on Mortality in Ambulatory Patients With HFrEF

CME/CE

VICTOR Prespecified Analysis Results: Vericiguat Effects on Mortality in Ambulatory Patients With HFrEF
OVICTOR Trial Results: Regional Variation in Outcomes and Response to Vericiguat in Patients With HFrEF

CME/CE

VICTOR Trial Results: Regional Variation in Outcomes and Response to Vericiguat in Patients With HFrEF
Effect of Vericiguat on Heart Failure Hospitalization Events in Ambulatory Patients With HFrEF: VICTOR Trial Prespecified Analysis

CME/CE

Effect of Vericiguat on Heart Failure Hospitalization Events in Ambulatory Patients With HFrEF: VICTOR Trial Prespecified Analysis
Optimizing Patient Outcomes in CKD & T2D Care With CONFIDENCE

CME/CE

Optimizing Patient Outcomes in CKD & T2D Care With CONFIDENCE
Optimizing Outcomes: Evidence-Based Strategies for Treating Patients With Heart Failure With Mildly Reduced or Preserved Left Ventricular Ejection Fraction

CME/CE

Optimizing Outcomes: Evidence-Based Strategies for Treating Patients With Heart Failure With Mildly Reduced or Preserved Left Ventricular Ejection Fraction
Redefining HF Care: The Role of Finerenone in Patients With LVEF ≥40%

CME/CE

Redefining HF Care: The Role of Finerenone in Patients With LVEF ≥40%
Optimize Outcomes in CKD & T2D: A Practical Approach to Initiating and Monitoring Combination ns-MRA & SGLT2i Therapy

CME/CE

Optimize Outcomes in CKD & T2D: A Practical Approach to Initiating and Monitoring Combination ns-MRA & SGLT2i Therapy
Addressing CKM Mortality & Morbidity in Patients With CKD and T2D: The Role of Combined ns-MRA & SGLT2i Therapy

CME/CE

Addressing CKM Mortality & Morbidity in Patients With CKD and T2D: The Role of Combined ns-MRA & SGLT2i Therapy
Expert Perspectives on Nonsteroidal MRAs and Cardiorenal Protection

CME/CE

Expert Perspectives on Nonsteroidal MRAs and Cardiorenal Protection
Topline Results of the CONFIDENCE Trial

CME/CE

Topline Results of the CONFIDENCE Trial
Impact of Finerenone on eGFR Slope by Baseline Albuminuria in FINEARTS-HF

CME/CE

Impact of Finerenone on eGFR Slope by Baseline Albuminuria in FINEARTS-HF
Albuminuria Change and Finerenone's Effect on CV Outcomes

CME/CE

Albuminuria Change and Finerenone's Effect on CV Outcomes
The CONFIDENCE Trial: Data Insights

CME/CE

The CONFIDENCE Trial: Data Insights

Nonsteroidal MRA & SGLT2i in People With CKD & T2D: Current Evidence and Rationale for Combination Therapy

CME/CE

Nonsteroidal MRA & SGLT2i in People With CKD & T2D: Current Evidence and Rationale for Combination Therapy
Shifting Treatment Paradigm in HFmrEF/HFpEF: Steroidal and Nonsteroidal MRAs

CME/CE

Shifting Treatment Paradigm in HFmrEF/HFpEF: Steroidal and Nonsteroidal MRAs
Innovative Approaches to Managing CKM Syndrome and HFmrEF/HFpEF

CME/CE

Innovative Approaches to Managing CKM Syndrome and HFmrEF/HFpEF
Novel Therapies in Managing Patients With Cardiovascular-Kidney-Metabolic Syndrome and Heart Failure

CME/CE

Novel Therapies in Managing Patients With Cardiovascular-Kidney-Metabolic Syndrome and Heart Failure
FINEARTS-HF Analysis of Patients With HFmrEF/HFpEF Both With and Without AF

CME/CE

FINEARTS-HF Analysis of Patients With HFmrEF/HFpEF Both With and Without AF
Effect of Finerenone on NT-proBNP in the FINEARTS-HF Trial

CME/CE

Effect of Finerenone on NT-proBNP in the FINEARTS-HF Trial
Kidney Risk Stratification in the FINEARTS-HF Trial

CME/CE

Kidney Risk Stratification in the FINEARTS-HF Trial
FINE-HEART Pooled Analysis

CME/CE

FINE-HEART Pooled Analysis
Mode of Death in Patients With HFmrEF/HFpEF From FINEARTS-HF

CME/CE

Mode of Death in Patients With HFmrEF/HFpEF From FINEARTS-HF
FINEARTS-HF Analysis Based on NYHA Functional Class

CME/CE

FINEARTS-HF Analysis Based on NYHA Functional Class
Bridging the Gap: ns-MRAs in Cardiovascular-Kidney-Metabolic Syndrome Care

MinuteCE®

Bridging the Gap: ns-MRAs in Cardiovascular-Kidney-Metabolic Syndrome Care
Optimizing Care for Patients With CKM Syndrome: A Multidisciplinary Approach

MinuteCE®

Optimizing Care for Patients With CKM Syndrome: A Multidisciplinary Approach
Expert Panel New Horizons: Unraveling Novel Therapies for Enhanced Cardiovascular Outcomes in Patients With Heart Failure

CME/CE

Expert Panel New Horizons: Unraveling Novel Therapies for Enhanced Cardiovascular Outcomes in Patients With Heart Failure
Check back soon!

Check back soon!

More programs will be added shortly.

Resource Center

Discover a curated collection of foundational, practical, and real-world educational resources at your fingertips. Click on a link to get started.

Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes

Agarwal R, Green JB, Heerspink HJL, Mann JFE, McGill JB, Mottl AK, Rosenstock J, Rossing P, Vaduganathan M, Brinker M, Edfors R, Li N, Scheerer MF, Scott C, Nangaku M; CONFIDENCE Investigators. Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes. N Engl J Med. 2025 Jun 5. doi: 10.1056/NEJMoa2410659. Epub ahead of print. PMID: 40470996.

The role of finerenone in the concomitant management of chronic kidney disease-type 2 diabetes and the implication for heart failure prevention and treatment

Taub PR, Greene SJ, Fudim M. The role of finerenone in the concomitant management of chronic kidney disease-type 2 diabetes and the implication for heart failure prevention and treatment. Heart Fail Rev. 2025 May 31. doi: 10.1007/s10741-025-10520-3. Epub ahead of print. PMID: 40448875.

Finerenone According to Frailty in Heart Failure: A Prespecified Analysis of the FINEARTS-HF Randomized Clinical Trial

Butt JH, Jhund PS, Henderson AD, et al. Finerenone According to Frailty in Heart Failure: A Prespecified Analysis of the FINEARTS-HF Randomized Clinical Trial. JAMA Cardiol. Published online June 18, 2025. doi:10.1001/jamacardio.2025.1775

Finerenone Reduces New-Onset Atrial Fibrillation across the Spectrum of Cardio-Kidney-Metabolism: the FINE-HEART Pooled Analysis

Maria A. Pabon, Gerasimos Filippatos, Brian L. Claggett, Michael Zi Miao, Akshay S. Desai, Pardeep S. Jhund, Alasdair Henderson, Meike Brinker, Patrick Schloemer, Lucas Hofmeister, Li Li, Carolyn S.P. Lam, Michele Senni, Sanjiv J. Shah, Adriaan A. Voors, Faiez Zannad, Peter Rossing, Luis M. Ruilope, Stefan D. Anker, Bertram Pitt, Rajiv Agarwal, John J.V. McMurray, Scott D. Solomon, Muthiah Vaduganathan, Finerenone Reduces New-Onset Atrial Fibrillation across the Spectrum of Cardio-Kidney-Metabolism: the FINE-HEART Pooled Analysis, JACC. 2025, ISSN 0735-1097, https://doi.org/10.1016/j.jacc.2025.03.429.

Finerenone and Atrial Fibrillation in Heart Failure: A Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial

Matsumoto S, Henderson AD, Jhund PS, et al. Finerenone and Atrial Fibrillation in Heart Failure: A Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial. JAMA Cardiol. Published online March 29, 2025. doi:10.1001/jamacardio.2025.0848

EFFICACY AND SAFETY OF FINERENONE ACROSS THE SPECTRUM OF KIDNEY RISK IN HEART FAILURE WITH MILDLY REDUCED OR PRESERVED EJECTION FRACTION

Ostrominski, J, Claggett, B, Causland, F. et al. EFFICACY AND SAFETY OF FINERENONE ACROSS THE SPECTRUM OF KIDNEY RISK IN HEART FAILURE WITH MILDLY REDUCED OR PRESERVED EJECTION FRACTION. JACC. 2025 Apr, 85 (12_Supplement) 1167.https://doi.org/10.1016/S0735-1097(25)01651-1

EFFECT OF FINERENONE ON N-TERMINAL PRO-B-TYPE NATRIURETIC PEPTIDE IN HEART FAILURE WITH MILDLY REDUCED OR PRESERVED EJECTION FRACTION: THE FINEARTS-HF TRIAL

Cunningham, J, Claggett, B, Vaduganathan, M. et al. EFFECT OF FINERENONE ON N-TERMINAL PRO-B-TYPE NATRIURETIC PEPTIDE IN HEART FAILURE WITH MILDLY REDUCED OR PRESERVED EJECTION FRACTION: THE FINEARTS-HF TRIAL. JACC. 2025 Apr, 85 (12_Supplement) 1203.

Mode of Death in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction: The FINEARTS-HF Randomized Clinical Trial

Desai AS, Jhund PS, Vaduganathan M, et al. Mode of Death in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The FINEARTS-HF Randomized Clinical Trial. JAMA Cardiol. Published online March 30, 2025. doi:10.1001/jamacardio.2025.0860

Finerenone, Obesity, and Heart Failure With Mildly Reduced/Preserved Ejection Fraction: Prespecified Analysis of FINEARTS-HF

Butt JH, Henderson AD, Jhund PS, et al. Finerenone, obesity, and heart failure with mildly reduced/preserved ejection fraction: prespecified analysis of FINEARTS-HF. J Am Coll Cardiol. 2025;85(2):140-155. doi:10.1016/j.jacc.2024.10.111

Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by diuretic use: A FIDELITY analysis

Mentz RJ, Anker SD, Pitt B, et al; on behalf of the FIDELIO‐DKD and FIGARO‐DKD Investigators. Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by diuretic use: a FIDELITY analysis. Eur J Heart Fail. Published online January 17, 2025. doi:10.1002/ejhf.3569

Finerenone and Kidney Outcomes in Patients With Heart Failure: The FINEARTS-HF Trial

Mc Causland FR, Vaduganathan M, Claggett BL, et al. Finerenone and kidney outcomes in patients with heart failure: the FINEARTS-HF trial. J Am Coll Cardiol. 2025;85(2):159-168. doi:10.1016/j.jacc.2024.10.091

Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

Solomon SD, McMurray JJV, Vaduganathan M, et al; FINEARTS-HF Committees and Investigators. Finerenone in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2024;391(16):1475-1485. doi:10.1056/NEJMoa2407107

Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis

Agarwal R, Filippatos G, Pitt B, et al; FIDELIO-DKD and FIGARO-DKD investigators. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022;43(6):474-484. doi:10.1093/eurheartj/ehab777

Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine

Agarwal R, Kolkhof P, Bakris G, et al. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur Heart J. 2021;42(2):152-161. doi:10.1093/eurheartj/ehaa736

Our Faculty

From academia to private practice, leading experts have joined together to advance the standard of CKM care worldwide:

Carolyn S. P. Lam, MBBS, PhD, MRCP, MS, FACC, FAMS, FESC

Carolyn S. P. Lam, MBBS, PhD, MRCP, MS, FACC, FAMS, FESC

Jürgen Floege, MD

Jürgen Floege, MD

Muthiah Vaduganathan, MD, MPH

Muthiah Vaduganathan, MD, MPH

Scott Solomon, MD

Scott Solomon, MD

Mikhail Kosiborod, MD

Mikhail Kosiborod, MD

Pardeep Jhund, MD, PhD

Pardeep Jhund, MD, PhD

Hiddo L. Heerspink, PhD

Hiddo L. Heerspink, PhD

John McMurray, MD

John McMurray, MD

Akshay S. Desai, MD

Akshay S. Desai, MD

Csaba P. Kovesdy, MD

Csaba P. Kovesdy, MD

Finnian R. Mc Causland, MD

Finnian R. Mc Causland, MD

Orly Vardeny, MD

Orly Vardeny, MD

References:

1. https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.120.050686


2. https://www.ncbi.nlm.nih.gov/books/NBK571718/


3. https://www.sciencedirect.com/science/article/abs/pii/S0033062024001488

This curriculum is provided by Medcon International, Inc.
Funding for this educational program was provided by an unrestricted educational grant from Bayer AG.